Last reviewed · How we verify

OROS hydromorphone HCL ; Morphine sulfate

Alza Corporation, DE, USA · Phase 3 active Small molecule

OROS hydromorphone HCL ; Morphine sulfate is a Opioid analgesic Small molecule drug developed by Alza Corporation, DE, USA. It is currently in Phase 3 development for Moderate to severe chronic pain requiring continuous opioid therapy.

OROS hydromorphone HCl is an extended-release opioid agonist that binds to mu opioid receptors in the central nervous system to provide prolonged pain relief.

OROS hydromorphone HCl is an extended-release opioid agonist that binds to mu opioid receptors in the central nervous system to provide prolonged pain relief. Used for Moderate to severe chronic pain requiring continuous opioid therapy.

At a glance

Generic nameOROS hydromorphone HCL ; Morphine sulfate
SponsorAlza Corporation, DE, USA
Drug classOpioid analgesic
TargetMu opioid receptor
ModalitySmall molecule
Therapeutic areaPain Management
PhasePhase 3

Mechanism of action

Hydromorphone is a semi-synthetic opioid that activates mu opioid receptors, inhibiting pain signal transmission and modulating pain perception. The OROS (osmotic release oral system) technology provides controlled, extended-release delivery over 24 hours, maintaining steady-state plasma concentrations and reducing dosing frequency. Morphine sulfate is also included as a reference comparator, being a natural opioid alkaloid with similar mu receptor agonist activity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about OROS hydromorphone HCL ; Morphine sulfate

What is OROS hydromorphone HCL ; Morphine sulfate?

OROS hydromorphone HCL ; Morphine sulfate is a Opioid analgesic drug developed by Alza Corporation, DE, USA, indicated for Moderate to severe chronic pain requiring continuous opioid therapy.

How does OROS hydromorphone HCL ; Morphine sulfate work?

OROS hydromorphone HCl is an extended-release opioid agonist that binds to mu opioid receptors in the central nervous system to provide prolonged pain relief.

What is OROS hydromorphone HCL ; Morphine sulfate used for?

OROS hydromorphone HCL ; Morphine sulfate is indicated for Moderate to severe chronic pain requiring continuous opioid therapy.

Who makes OROS hydromorphone HCL ; Morphine sulfate?

OROS hydromorphone HCL ; Morphine sulfate is developed by Alza Corporation, DE, USA (see full Alza Corporation, DE, USA pipeline at /company/alza-corporation-de-usa).

What drug class is OROS hydromorphone HCL ; Morphine sulfate in?

OROS hydromorphone HCL ; Morphine sulfate belongs to the Opioid analgesic class. See all Opioid analgesic drugs at /class/opioid-analgesic.

What development phase is OROS hydromorphone HCL ; Morphine sulfate in?

OROS hydromorphone HCL ; Morphine sulfate is in Phase 3.

What are the side effects of OROS hydromorphone HCL ; Morphine sulfate?

Common side effects of OROS hydromorphone HCL ; Morphine sulfate include Constipation, Nausea, Dizziness, Somnolence, Vomiting, Headache.

What does OROS hydromorphone HCL ; Morphine sulfate target?

OROS hydromorphone HCL ; Morphine sulfate targets Mu opioid receptor and is a Opioid analgesic.

Related